Before starting tirzepatide or semaglutide, it is important to talk to your doctor to see if they are the right choice based on your health and treatment goals
1 Thus, their clinical use is expected to grow rapidly not only because of the obesity epidemic but as evidence expands to other indications such as cardiorenal disorders, metabolic liver disease, obstructive sleep apnea, peripheral vascular disease, depression, addiction, and neurodegenerative diseases
Es una sustancia proaterognica que est asociada con riesgos de enfermedad cardiovascular
Failure to Adequately Warn Patients About Known Risks The master complaint filed in MDL 3094 alleges that Novo Nordisk and Eli Lilly knew or should have known about the severe gastroparesis and vision loss risks associated with their GLP-1 medications but failed to provide adequate warnings on product labels, marketing materials, or prescribing information